Revolution Medicines' general counsel, Jeff Cislini, completed two stock sales in March that together disposed of 2,958 shares of the company's common stock and generated approximately $291,889 in proceeds.
The first transaction occurred on March 17, 2026, when Cislini sold 1,795 shares at $99.4804 per share, yielding $178,567. A second sale on March 19, 2026 involved 1,163 shares sold at $97.44 per share, producing $113,322.
Documentation accompanying the March 17 sale indicates it was executed under a Rule 10b5-1 instruction letter that Cislini adopted on May 31, 2023. That instruction letter was put in place to cover tax obligations associated with the vesting of restricted stock units. The March 19 transaction, by contrast, was carried out pursuant to a separate 10b5-1 trading plan that Cislini adopted on March 13, 2025.
After these two dispositions, Cislini directly owns 58,518 shares of Revolution Medicines, Inc., a holding that includes 48,125 restricted stock units.
The sales took place with Revolution Medicines' stock trading at $99.29, a level the company notes is close to its 52-week high of $124.49. Over the past year the shares have recorded a substantial gain of 156%.
Beyond insider activity, the company’s recent financial results and analyst reactions provide additional context.
Revolution Medicines reported fourth-quarter 2025 results showing an 87% year-over-year increase in its net loss. The company posted a loss of $1.86 per share for the quarter, which was roughly 18% wider than consensus expectations; the shortfall was attributed to higher research and development and administrative expenses.
Despite the expanded loss, the company finished the quarter with $2.03 billion in cash and investments, a position supported in part by a partnership with Royalty Pharma.
Following the earnings release, several sell-side firms updated their views: UBS initiated coverage with a Buy rating that highlighted the potential of the company’s RAS inhibitors in treating a range of cancers. Piper Sandler raised its price target to $120 and maintained an Overweight rating. Needham adjusted its price target to $145 from $150 while keeping a Buy rating. Wells Fargo increased its price target to $144 and cited confidence in the company’s trajectory toward pivotal clinical trial results expected in the first half of 2026.
Market-data commentary from InvestingPro suggests the stock appears slightly overvalued relative to its Fair Value, while noting the company’s net cash position exceeds its debt. Investors seeking additional commentary and analysis can access 10 further ProTips and a full Pro Research Report through the InvestingPro platform.
These insider sales, the company’s recent financial performance and the post-earnings analyst activity together form the immediate public picture of Revolution Medicines’ position. Cislini retains a sizable stake in the company even after the March transactions, and the firm’s balance sheet and analyst interest remain relevant factors for market participants monitoring RVMD.